Regarding the warning letter that a subsidiary of ZOLL Medical Corporation (ZOLL) received from the U.S. Food and Drug Administration (FDA) as announced on October 15, 2014, the subsidiary of ZOLL received a letter from the FDA dated October 29, 2015, providing notification that the FDA’s evaluation of the corrective actions taken by the company indicates that the concerns raised in the warning letter have been addressed.